growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges.

Rational molecular design, chemical synthesis and Virometix' proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.